AAPL   320.40 (+0.77%)
MSFT   182.05 (-0.65%)
FB   228.18 (+1.37%)
GOOGL   1,431.92 (-0.11%)
AMZN   2,464.00 (+0.89%)
NVDA   349.67 (-1.51%)
CGC   16.10 (-7.31%)
BABA   204.76 (-1.27%)
MU   46.82 (-2.28%)
GE   6.74 (+2.59%)
TSLA   881.58 (+5.58%)
F   5.84 (+2.10%)
DIS   119.19 (+1.61%)
NFLX   420.29 (+0.13%)
BAC   24.74 (+2.57%)
BA   151.91 (+4.15%)
AAPL   320.40 (+0.77%)
MSFT   182.05 (-0.65%)
FB   228.18 (+1.37%)
GOOGL   1,431.92 (-0.11%)
AMZN   2,464.00 (+0.89%)
NVDA   349.67 (-1.51%)
CGC   16.10 (-7.31%)
BABA   204.76 (-1.27%)
MU   46.82 (-2.28%)
GE   6.74 (+2.59%)
TSLA   881.58 (+5.58%)
F   5.84 (+2.10%)
DIS   119.19 (+1.61%)
NFLX   420.29 (+0.13%)
BAC   24.74 (+2.57%)
BA   151.91 (+4.15%)
AAPL   320.40 (+0.77%)
MSFT   182.05 (-0.65%)
FB   228.18 (+1.37%)
GOOGL   1,431.92 (-0.11%)
AMZN   2,464.00 (+0.89%)
NVDA   349.67 (-1.51%)
CGC   16.10 (-7.31%)
BABA   204.76 (-1.27%)
MU   46.82 (-2.28%)
GE   6.74 (+2.59%)
TSLA   881.58 (+5.58%)
F   5.84 (+2.10%)
DIS   119.19 (+1.61%)
NFLX   420.29 (+0.13%)
BAC   24.74 (+2.57%)
BA   151.91 (+4.15%)
AAPL   320.40 (+0.77%)
MSFT   182.05 (-0.65%)
FB   228.18 (+1.37%)
GOOGL   1,431.92 (-0.11%)
AMZN   2,464.00 (+0.89%)
NVDA   349.67 (-1.51%)
CGC   16.10 (-7.31%)
BABA   204.76 (-1.27%)
MU   46.82 (-2.28%)
GE   6.74 (+2.59%)
TSLA   881.58 (+5.58%)
F   5.84 (+2.10%)
DIS   119.19 (+1.61%)
NFLX   420.29 (+0.13%)
BAC   24.74 (+2.57%)
BA   151.91 (+4.15%)
Log in

NASDAQ:NTRPNeurotrope Stock Price, Forecast & News

$1.43
+0.04 (+2.88 %)
(As of 06/1/2020 11:18 AM ET)
Add
Compare
Today's Range
$1.38
Now: $1.43
$1.43
50-Day Range
$0.99
MA: $1.27
$1.47
52-Week Range
$0.63
Now: $1.43
$8.40
Volume1,214 shs
Average Volume588,545 shs
Market Capitalization$29.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.27
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.
Read More
Neurotrope logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRP
CUSIPN/A
Phone973-242-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.33 per share

Profitability

Net Income$-15,140,000.00

Miscellaneous

Employees6
Market Cap$29.96 million
Next Earnings Date6/4/2020 (Estimated)
OptionableOptionable

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.

Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

How has Neurotrope's stock been impacted by COVID-19 (Coronavirus)?

Neurotrope's stock was trading at $0.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NTRP shares have increased by 64.4% and is now trading at $1.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neurotrope?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Neurotrope.

When is Neurotrope's next earnings date?

Neurotrope is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for Neurotrope.

How were Neurotrope's earnings last quarter?

Neurotrope Inc (NASDAQ:NTRP) released its quarterly earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. View Neurotrope's earnings history.

What price target have analysts set for NTRP?

2 Wall Street analysts have issued twelve-month price objectives for Neurotrope's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Neurotrope's stock price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 30.1%. View analysts' price targets for Neurotrope.

Has Neurotrope been receiving favorable news coverage?

News headlines about NTRP stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurotrope earned a news impact score of 1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutNeurotrope.

Who are some of Neurotrope's key competitors?

What other stocks do shareholders of Neurotrope own?

Who are Neurotrope's key executives?

Neurotrope's management team includes the following people:
  • Dr. Charles S. Ryan, CEO & Director (Age 55)
  • Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
  • Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
  • Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)
  • Mr. Jeffrey Benison, Director of Corp. Communications

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

Who are Neurotrope's major shareholders?

Neurotrope's stock is owned by a number of institutional and retail investors. Top institutional investors include Acorn Financial Advisory Services Inc. ADV (1.27%), FNY Investment Advisers LLC (0.38%) and One68 Global Capital LLC (0.14%). View institutional ownership trends for Neurotrope.

Which institutional investors are buying Neurotrope stock?

NTRP stock was bought by a variety of institutional investors in the last quarter, including Acorn Financial Advisory Services Inc. ADV, FNY Investment Advisers LLC, and One68 Global Capital LLC. View insider buying and selling activity for Neurotrope.

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $1.43.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $29.96 million. Neurotrope employs 6 workers across the globe.

What is Neurotrope's official website?

The official website for Neurotrope is www.neurotrope.com.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.